Clinical Trial Update: Endostar Combined With IP Second-line Treatment of Advanced Esophageal Squamous Cell Carcinomas [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating Endostar in combination with the IP chemotherapy regimen (irinotecan + cisplatin) for second-line treatment of advanced esop…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Squamous Cell Carcinoma

Drugs mentioned

• CISPLATIN (cisplatin)
• Endostar (recombinant human endostatin)
• Irinotecan (Irinotecan)

Snippet

Sponsor: Fudan University | Conditions: Esophageal Squamous Cell Carcinoma | Phase 2 | Status: COMPLETED